Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Pneumosil in Vietnamese Infants
NCT05140720Phase 3Unknown
- Sponsor
- Vabiotech
- Start
- Jan 2022
- Primary completion
- Feb 2022
- Modality
- Split/Subunit Vaccines
01
Overview
Phase 3, open-label trial of SIILPCV10 in pneumococcal disease (3 arms), sponsored by Vabiotech. Primary endpoints: Percent of participants with immediate solicited adverse events, Percent of participants with solicited adverse events within 7 days and 2 more. Status: unknown.
02
Drugs
SIILPCV10
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT05140720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05140720.